https://scholars.lib.ntu.edu.tw/handle/123456789/484094
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | LI-CHUN LU | en_US |
dc.contributor.author | YU-YUN SHAO | en_US |
dc.contributor.author | Kuo R.N.C. | en_US |
dc.contributor.author | ZHONG-ZHE LIN | en_US |
dc.contributor.author | Yeh Y.-C. | en_US |
dc.contributor.author | Shau W.-Y. | en_US |
dc.contributor.author | CHIH-HUNG HSU | en_US |
dc.contributor.author | ANN-LII CHENG | en_US |
dc.contributor.author | Lai M.-S. | en_US |
dc.creator | Lai M.-S.;Cheng A.-L.;Hsu C.-H.;Shau W.-Y.;Yeh Y.-C.;Lin Z.-Z.;Kuo R.N.C.;YU-YUN SHAO;Lu L.-C. | - |
dc.date.accessioned | 2020-04-10T12:16:09Z | - |
dc.date.available | 2020-04-10T12:16:09Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 0008-543X | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84874690099&doi=10.1002%2fcncr.27800&partnerID=40&md5=8b491713aa0ea8dec1fff0d54211c50f | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/484094 | - |
dc.description.abstract | Background: Hospital volume for several major operations is associated with treatment outcomes. In this study, the authors explored the influence of hospital radiofrequency ablation (RFA) volume on the prognosis of patients who received RFA for hepatocellular carcinoma (HCC). METHODS: The authors searched for all patients who were diagnosed with stage I or stage II HCC from 2004 to 2006 and who received RFA as first-line therapy in a population-based cohort. Overall survival (OS) and liver cancer-specific survival (CSS) were compared according to hospital volume. A Cox proportional hazards model was used for multivariate analysis. RESULTS: In total, 661 patients received first-line RFA for stage I and II HCC in 28 hospitals. Among these, there were 480 patients (72.6%) in the high-volume group (those who received RFA at hospitals that treated >10 first-line patients per year), and there were 181 patients (27.4%) in the low-volume group (those who received RFA at hospitals that treated ?10 first-line patients per year). The sex, age, stage, tumor size, and year of diagnosis for patients in the 2 groups did not differ significantly. Patients in the high-volume group demonstrated significantly longer OS and CSS than those in the low-volume group (5-year OS rate, 58.7% vs 47.2%; P =.001; 5-year CSS rate, 67.1% vs 57.1%; P =.009). After adjusting for covariates, high-volume hospitals remained an independent predictor of longer OS (hazard ratio, 0.57; P <.001) and CSS (hazard ratio, 0.57; P =.003). CONCLUSIONS: Patients who received first-line RFA for HCC in high-volume hospitals demonstrated better survival outcomes. Cancer 2013. ? 2012 American Cancer Society. | - |
dc.relation.ispartof | Cancer | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | adult; age distribution; aged; article; cancer prognosis; cancer specific survival; cancer staging; cohort analysis; controlled study; female; hospital patient; human; liver cell carcinoma; major clinical study; male; overall survival; population research; priority journal; radiofrequency ablation; sex difference; survival rate; treatment outcome; tumor volume; Carcinoma, Hepatocellular; Catheter Ablation; Female; Humans; Liver Neoplasms; Male; Surgery Department, Hospital; Survival Rate; Treatment Outcome | - |
dc.title | Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1002/cncr.27800 | - |
dc.identifier.pmid | 23212657 | - |
dc.identifier.scopus | 2-s2.0-84874690099 | - |
dc.relation.pages | 1210-1216 | - |
dc.relation.journalvolume | 119 | - |
dc.relation.journalissue | 6 | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Medical Service-NTUCC | - |
crisitem.author.dept | Medical Oncology-NTUCC | - |
crisitem.author.dept | Center for Quality Management and Infection Control-NTUCC | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Medical Oncology-NTUCC | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Cancer Administration and Coordination Center | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.orcid | 0000-0001-8975-9491 | - |
crisitem.author.orcid | 0000-0001-7334-1912 | - |
crisitem.author.orcid | 0000-0003-0495-973X | - |
crisitem.author.orcid | 0000-0002-9152-6512 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。